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for the CoreValve US Pivotal Trial InvestigatorsABSTRACTFro
Mi
HoOBJECTIVES This study sought to compare the health status outcomes for patients treated with either self-expanding
transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (AVR).
BACKGROUND In patients at increased surgical risk, TAVR with a self-expanding bioprosthesis is associated with
improved 1-year survival compared with AVR. However, elderly patients may be just as concerned with quality-of-life
improvement as with prolonged survival as a goal of treatment.
METHODS Between 2011 and 2012, 795 patients with severe aortic stenosis at increased surgical risk were randomized
to TAVR or AVR in the CoreValve US Pivotal Trial. Health status was assessed at baseline, 1 month, 6 months, and 1 year
using the Kansas City Cardiomyopathy Questionnaire, Medical Outcomes Study Short-Form 12 Questionnaire, and
EuroQOL 5-dimension questionnaire; growth curve models were used to examine changes over time.
RESULTS Over the 1-year follow-up period, disease-speciﬁc and generic health status improved substantially for both
treatment groups. At 1 month, there was a signiﬁcant interaction between the beneﬁt of TAVR over AVR and access site.
Among surviving patients eligible for iliofemoral (IF) access, there was a clinically relevant early beneﬁt with TAVR across all
disease-speciﬁc and generic health status measures. Among the non-IF cohort, however, most health status measures were
similar for TAVR and AVR, although there was a trend toward early beneﬁt with TAVR on the Short-Form 12 Questionnaire’s
physical health scale. There were no consistent differences in health status between TAVR and AVR at the later time points.
CONCLUSIONS Health status improved substantially in surviving patients with increased surgical risk who were treated
with either self-expanding TAVR or AVR. TAVR via the IF route was associated with better early health status com-
pared with AVR, but there was no early health status beneﬁt with non-IF TAVR compared with AVR. (Safety and Efﬁcacy
Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and
Very High Risk Subjects Who Need Aortic Valve Replacement; NCT01240902) (J Am Coll Cardiol Intv 2015;8:1207–17)
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Association
SF-12 = Medical Outcomes
Study Short-Form 12
Questionnaire
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1208W hereas patients with severeaortic stenosis previously hadto choose between surgical
aortic valve replacement (AVR) or medical
therapy, over the last decade transcatheter
aortic valve replacement (TAVR) has
emerged as a viable alternative to these
treatment options. Less invasive than AVR,
TAVR with a balloon-expandable valve has
been shown to have superior outcomes
compared with medical therapy for both
mortality (1) and quality of life (2). Among
patients at increased risk for surgery,
balloon-expandable TAVR has similar late
outcomes to AVR (3), although TAVR per-
formed via the transfemoral route did show
improved early quality of life comparedwith AVR (4).
Recently, an alternative TAVR platform with a self-
expanding bioprosthesis (CoreValve, Medtronic, Inc.,
Minneapolis, Minnesota) was shown to be associated
with improved survival at 1 year compared with AVR
in patients at increased surgical risk (5). Although
improved survival is an unequivocally important
beneﬁt of the CoreValve, how this device affects
patients’ symptoms, functional status, and quality of
life compared with AVR is unknown. Because the self-
expanding bioprosthesis differs from the balloon-
expandable valve in terms of the device itself, the
risk of particular complications (e.g., paravalvular
regurgitation, new pacemaker), and in the device
delivery (e.g., smaller sheath size, different alterna-
tive access sites), the health status outcomes of pa-
tients treated with these different devices may also
be different. These outcomes are particularlyospital, Morristown, New Jersey; **Mount Sinai Medical Center, N
nter, Boston, Massachusetts. The CoreValve US Pivotal trial was
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received April 17, 2015; accepted April 23, 2015.important, because elderly patients with multiple
comorbidities—the typical population for whom TAVR
would be considered—may be more concerned with
quality of life than prolonged survival (6,7). To
address this gap in knowledge, we used data from the
CoreValve US High Risk Pivotal Trial to compare the
health status outcomes for patients with aortic ste-
nosis who are at increased surgical risk and are
treated with either self-expanding TAVR or AVR.
METHODS
PATIENT POPULATION AND STUDY PROTOCOL.
The design of the CoreValve US High Risk Pivotal
Trial, including inclusion and exclusion criteria,
study procedures, and follow-up protocols, was
published previously (5). Brieﬂy, the trial enrolled
patients with severe, symptomatic aortic stenosis
who were considered to be at increased risk for peri-
operative mortality with AVR. Severe aortic stenosis
was deﬁned as: 1) aortic valve area #0.8 cm2 or aortic
valve area index #0.5 cm2/m2; and 2) mean aortic
valve gradient >40 mm Hg or peak aortic jet velocity
>4.0 m/s. Patients also had to have New York Heart
Association (NYHA) functional class II or higher heart
failure symptoms and be considered to be at
increased surgical risk—deﬁned as a risk of death
within 30 days after surgery of $15%, as estimated by
2 cardiac surgeons and 1 interventional cardiologist at
the investigative site. Patient risk eligibility was also
conﬁrmed by consensus among at least 2 senior car-
diac surgeons and 1 interventional cardiologist who
were members of the national screening committee.
The approach for the TAVR procedure (iliofemoral
[IF] or noniliofemoral [NIF] [performed either viaew York, New York; and the yyBeth Israel Deaconess
sponsored by Medtronic. All analyses, the prepara-
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1209subclavian artery or direct aortic approach]) was
determined using computed tomography. Patients
were then randomly assigned in a 1:1 ratio to treat-
ment with TAVR or AVR. Randomization was strati-
ﬁed according to investigational site and intended
access site (IF or NIF). The study was approved by the
institutional review board at each investigational site,
and all patients provided written informed consent.
HEALTH STATUS MEASURES. Disease-speciﬁc and
generic health status was assessed at baseline and at
1 month, 6 months, and 1 year after enrollment using
validated written questionnaires. Baseline question-
naires were administered in person after enrollment
but before the implant procedure. Follow-up ques-
tionnaires were administered by mail from a central
coordinating center. Surveys thatwere not returned by
mail in a timely fashion were administered by tele-
phone interview. Non-English speakers completed
validated translations of the questionnaires.
Disease-speciﬁc health status was assessed using
the Kansas City Cardiomyopathy Questionnaire
(KCCQ) (8), a 23-item self-administered questionnaire
that has been shown to be a reliable and valid mea-
sure of symptoms, functional status, and quality of
life in patients with heart failure symptoms,
including those with severe, symptomatic aortic
stenosis (9). The KCCQ assesses speciﬁc health
domains—physical limitation, symptoms, quality of
life, social limitation, and self-efﬁcacy—the ﬁrst 4 of
which are combined into an overall summary score,
which was the pre-deﬁned primary endpoint for this
study. Values for all KCCQ domains and the summary
score range from 0 to 100, with higher scores indi-
cating less symptom burden and better quality of life.
The KCCQ overall summary score generally correlates
with NYHA functional class as follows: class I: KCCQ
75 to 100; class II: 60 to 74; class III: 45 to 59; class IV:
0 to 44 (9,10). Changes in the KCCQ of 5, 10, and
20 points correspond to small, moderate, or large
clinical improvements, respectively (10).
Generic health status was evaluated with the
Medical Outcomes Study Short-Form 12 (SF-12) ques-
tionnaire (11) and the EuroQOL 5-dimension ques-
tionnaire (EQ-5D) (12). Derived from the Short-Form
36, the SF-12 provides mental and physical summary
scores that are scaled to overall U.S. norms of 50 and
an SD of 10, with higher scores indicating better
quality of life (11). The minimum clinically important
difference for the SF-12 physical and mental summary
scores is w2 points (13). The EQ-5D is a generic health
status measure consisting of 5 domains (mobility, self-
care, usual activities, pain/discomfort, and anxiety/
depression) that can be converted to utilities using analgorithm developed for the U.S. population (14).
Utilities are preference-based health status measures
and range from 0 to 1, with 1 representing perfect
health and 0 corresponding to the worst imaginable
health state (15).
In addition to examining the disease-speciﬁc and
generic health status of survivors, we also examined
rates of acceptable and favorable outcomes after
TAVR using deﬁnitions that combined mortality and
quality of life into a single outcome (16). As previ-
ously described, an acceptable outcome was deﬁned
as the presence of all of the following at 6 months:
1) alive; 2) KCCQ overall summary score $45 (roughly
equivalent to NYHA functional class III or better); and
3) stability or improvement in the KCCQ score from
baseline to 6 months (decrease of <10 points).
A favorable outcome was deﬁned as all of the
following at 1 year: 1) alive; 2) KCCQ overall summary
score $60 (roughly equivalent to NYHA functional
class I to II); and 3) stability or improvement in the
KCCQ score from baseline to 6 months (decrease
of <10 points) (17).
STATISTICAL ANALYSIS. The primary analysis com-
pared the health status of patients randomized to
TAVR versus AVR on an intention-to-treat basis. As a
secondary analysis, we compared treatments using a
per-protocol approach, where patients were included
only if they received their assigned treatment via
the assigned access route. Baseline characteristics,
including health status, were compared between
groups using 2-sample Student t tests for continuous
variables and chi-square tests for categorical vari-
ables. Mean follow-up health status scores at
1 month, 6 months, and 1 year were compared with
baseline within each treatment group using paired
Student t tests. Rates of acceptable and favorable
outcomes at 6 months and 1 year, respectively, were
compared between groups using chi-square tests.
For each of the primary and secondary health
status outcomes, longitudinal random-effects
growth curve models were used to examine the
relative effect of TAVR versus AVR over time (18).
These growth curve models incorporate all available
health status data from all follow-up time points,
including those for patients who subsequently died,
withdrew from the study, or were lost to follow-up.
The models included baseline health status, TAVR
access site (IF vs. NIF), treatment assignment, and
the interaction between access site and treatment
group. The pre-deﬁned analytic plan speciﬁed that if
a signiﬁcant interaction (p < 0.05) between treat-
ment assignment and access site was observed on
the KCCQ overall summary score at any time point,
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1210then all health status outcomes would be analyzed
separately for the IF and NIF groups. The models
also considered age, sex, and severe chronic
obstructive pulmonary disease. The intercept and
linear effects of time were estimated using both
ﬁxed and random effects. Cubic and quadraticTABLE 1 Baseline Characteristics and Health Status, Stratiﬁed by Acc
Iliofem
TAVR (n ¼ 315) AVR
Demographic and clinical characteristics
Age, yrs 83.4  6.9 83
Male sex 53.3
Previous myocardial infarction 22.2
Previous bypass surgery 30.8
Previous angioplasty 33.0
Previous balloon valvuloplasty 4.8
Previous permanent pacemaker 24.1
Previous stroke or TIA 17.1
Peripheral vascular disease 36.9
Atrial ﬁbrillation/ﬂutter 41.0
Chronic lung disease 44.8
Home oxygen 13.7
Diabetes mellitus 33.0
Chronic kidney disease
Stage 4–5 10.5
Stage 3 60.0
Disease severity
Left ventricular ejection fraction, % 58.0  11.1 57
Mean aortic valve gradient, mm Hg 48.5  15.3 47
Aortic valve area, cm2 0.7  0.2 0
NYHA functional class
II 13.3
III 64.8
IV 21.9
STS mortality risk score, % risk of mortality 7.3  3.1 7
Logistic EuroSCORE, % risk of mortality 18.1  13.3 18
Disability and frailty measures
Wheelchair bound 4.4
Does not live independently 9.5
Body mass index <21 kg/m2 4.1
Albumin <3.3 g/dl 16.7
Unplanned weight loss 9.5
5-m gait speed, s 9.6  9.2 9
Health status scores
KCCQ
Overall summary 45.9  23.6 46
Physical limitations 45.7  25.2 45
Total symptoms 55.4  25.0 54.
Quality of life 40.7  24.8 42
Social limitation 40.5  30.4 40
SF-12
Physical summary 30.6  9.0 30
Mental summary 47.0  12.3 48
EQ-5D utility 0.73  0.20 0.7
Values are mean  SD or %.
KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; NYHA ¼ New York Heart Assoc
ischemic attack.effects of time were considered (both terms were not
included in the same model to avoid over-
parameterization) as well as all 2- and 3-way in-
teractions between treatment, time, and TAVR
access site. Starting with the highest order time-by-
treatment interaction, variables were retained iness Site
oral Noniliofemoral
(n ¼ 280) p Value TAVR (n ¼ 61) AVR (n ¼ 53) p Value
.5  6.3 0.851 81.9  8.1 83.4  6.5 0.282
53.2 0.977 50.8 50.9 0.989
23.9 0.622 37.7 28.3 0.288
30.4 0.908 21.3 34.0 0.130
38.6 0.158 44.3 37.7 0.480
6.8 0.288 13.1 7.5 0.334
22.5 0.640 16.4 17.0 0.933
19.3 0.498 14.8 32.7 0.024
37.1 0.962 62.3 67.9 0.530
49.3 0.041 41.7 39.6 0.825
46.1 0.749 44.3 34.0 0.262
11.8 0.487 8.2 5.7 0.722
43.9 0.006 39.3 39.6 0.976
0.975 0.927
10.4 14.8 13.2
60.4 57.4 60.4
.3  11.8 0.472 57.1  13.6 58.6  12.6 0.563
.9  14.4 0.638 46.7  16.5 46.5  11.8 0.943
.7  0.2 0.420 0.7  0.2 0.7  0.2 0.624
12.1 0.664 18.0 20.8 0.713
69.6 0.206 68.9 66.0 0.749
18.2 0.263 13.1 13.2 0.988
.6  3.2 0.320 7.2  2.6 7.7  4.1 0.465
.6  13.1 0.656 16.5  12.4 20.8  13.3 0.078
3.9 0.754 0.0 7.5 0.044
8.9 0.802 8.2 7.5 1.000
3.6 0.726 16.4 11.3 0.437
16.1 0.843 11.5 10.0 0.803
6.1 0.119 8.2 9.4 1.000
.8  8.4 0.787 9.0  3.5 8.6  3.6 0.561
.0  22.4 0.958 51.5  22.1 51.2  21.0 0.938
.7  25.1 0.992 50.9  22.9 47.9  24.9 0.501
6  24.6 0.678 59.9  22.4 61.2  23.6 0.768
.1  23.7 0.492 45.9  24.7 45.1  23.8 0.865
.5  29.6 0.978 48.5  30.9 49.4  28.0 0.872
.7  8.4 0.935 31.4  10.1 32.8  9.0 0.437
.7  11.6 0.094 49.5  10.5 46.8  11.7 0.198
3  0.17 0.607 0.76  0.14 0.72  0.21 0.229
iation; SF-12 ¼ Short Form-12; STS ¼ Society of Thoracic Surgeons; TIA ¼ transient
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 9 , 2 0 1 5 Arnold et al.
A U G U S T 1 7 , 2 0 1 5 : 1 2 0 7 – 1 7 Quality of Life After TAVR With CoreValve vs. AVR
1211the model if p < 0.05 using a backward stepwise
selection process. Estimates of differences in mean
scores between treatment groups and 95% conﬁ-
dence intervals were obtained at each follow-up
time point from these growth curve models. All an-
alyses were performed using SAS version 9.3 (SAS
Institute, Cary, North Carolina), and all tests were 2-
tailed with a nominal type 1 error rate of 5% and no
adjustments for multiple comparisons.
RESULTS
PATIENT POPULATION. From 2011 to 2012, 795 patients
with severe, symptomatic aortic stenosis from 45 U.S.
centers were randomized to either self-expanding TAVR
(n ¼ 394) or AVR (n ¼ 401) in the CoreValve US High RiskTABLE 2 Within-Group Comparisons of Health Status After TAVR: Ili
TAVR
n Paired Difference* (95% CI)
KCCQ
Overall summary
1 month 210 21.6 (17.7 to 25.5)
6 months 230 25.8 (22.4 to 29.2)
1 year 205 24.0 (20.6 to 27.5)
Physical limitations
1 month 184 16.5 (12.0 to 21.1)
6 months 207 15.8 (12.1 to 19.6)
1 year 178 14.8 (10.5 to 19.0)
Total symptoms
1 month 209 16.7 (13.0 to 20.4)
6 months 230 21.4 (17.8 to 25.0)
1 year 205 18.1 (14.5 to 21.7)
Quality of life
1 month 207 30.3 (26.1 to 34.5)
6 months 224 36.5 (32.6 to 40.4)
1 year 202 34.2 (30.4 to 38.0)
Social limitation
1 month 166 20.8 (15.3 to 26.3)
6 months 187 26.5 (21.4 to 31.5)
1 year 163 25.8 (20.7 to 31.0)
SF-12
Physical summary
1 month 186 5.4 (4.0 to 6.9)
6 months 210 6.3 (4.8 to 7.8)
1 year 187 5.9 (4.2 to 7.5)
Mental summary
1 month 186 3.5 (1.7 to 5.4)
6 months 210 5.2 (3.5 to 6.8)
1 year 187 4.8 (3.0 to 6.5)
EQ-5D utility
1 month 204 0.055 (0.024 to 0.087)
6 months 221 0.053 (0.023 to 0.082)
1 year 199 0.043 (0.015 to 0.071)
*Paired differences reﬂect changes compared with baseline.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.Pivotal Trial. Health status data were available for 709 pa-
tients (89%) at baseline, which formed our analytic cohort.
Overall, the patients were elderly (mean age 83 years), had
a high burden of cardiac and noncardiac comorbidities,
had severe aortic stenosis (average mean gradient
48mmHg), and had substantial functional limitations due
to heart failure symptoms (67% NYHA functional class III,
19% NYHA functional class IV). Frailty indicators were
common, with 9% of patients not living independently,
low serum albumin (amarker of chronic disease) in 16% of
patients, and an average 5-m walk time of 9.5 s (gait
speed$6 s is considered slow and a marker of frailty).
A total of 84% of patients were eligible for IF
access, whereas 16% required NIF access, which was
performed either via subclavian artery or direct aortic
approach. The baseline characteristics of theseofemoral Group
AVR
p Value n Paired Difference* (95% CI) p Value
<0.001 149 3.5 (1.0 to 7.9) 0.127
<0.001 175 24.2 (20.2 to 28.2) <0.001
<0.001 163 21.8 (17.5 to 26.0) <0.001
<0.001 134 3.1 (8.2 to 2.1) 0.240
<0.001 157 14.7 (10.1 to 19.2) <0.001
<0.001 154 11.1 (6.3 to 15.9) <0.001
<0.001 148 5.2 (0.6 to 9.7) 0.026
<0.001 175 21.1 (17.1 to 25.0) <0.001
<0.001 163 18.5 (14.2 to 22.8) <0.001
<0.001 147 10.2 (5.2 to 15.2) <0.001
<0.001 172 32.4 (27.6 to 37.3) <0.001
<0.001 160 33.6 (28.9 to 38.2) <0.001
<0.001 119 0.7 (7.8 to 6.4) 0.853
<0.001 142 28.4 (22.9 to 34.0) <0.001
<0.001 135 23.4 (17.6 to 29.3) <0.001
<0.001 137 0.0 (1.7 to 1.7) 0.992
<0.001 159 6.8 (5.3 to 8.3) <0.001
<0.001 147 5.1 (3.4 to 6.7) <0.001
<0.001 137 2.9 (5.1 to 0.7) 0.011
<0.001 159 2.7 (0.7 to 4.6) 0.009
<0.001 147 2.9 (0.9 to 4.9) 0.004
<0.001 144 0.073 (0.116 to 0.030) 0.001
<0.001 173 0.040 (0.014 to 0.065) 0.003
0.003 155 0.003 (0.029 to 0.035) 0.870
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1212patients, stratiﬁed by access site (IF vs. NIF), are
shown in Table 1. Patients who required NIF access
generally had more cardiac comorbidities, more pe-
ripheral vascular disease, and lower body weights
compared with those who were eligible for IF access.
The treatment groups were well-matched, with only
minor differences between groups.
Baseline health status, stratiﬁed by access site, is
shown in Table 1. In the overall population, the mean
KCCQ overall summary score was 46.8 points, which is
generally consistent with NYHA functional class III
symptoms. The mean SF-12 physical summary score
was 30.9 points (w2 SDs below population mean), and
the mean SF-12 mental summary score was 47.9 points
(near population mean). Mean EQ-5D utility was 0.73.
Patients who required NIF access generally had higherTABLE 3 Within-Group Comparisons of Health Status After TAVR: No
TAVR
n Paired Difference* (95% CI)
KCCQ
Overall summary
1 month 34 3.3 (7.3 to 13.9)
6 months 39 19.0 (9.3 to 28.7)
1 year 38 18.7 (9.2 to 28.1)
Physical limitations
1 month 29 4.6 (17.5 to 8.4)
6 months 37 12.3 (0.2 to 24.4)
1 year 36 11.9 (0.2 to 23.9)
Total symptoms
1 month 34 3.2 (6.3 to 12.6)
6 months 39 15.9 (8.0 to 23.8)
1 year 38 13.0 (5.1 to 21.0)
Quality of life
1 month 34 12.6 (0.1 to 25.3)
6 months 39 27.4 (17.4 to 37.3)
1 year 36 22.8 (11.6 to 34.0)
Social limitation
1 month 27 4.2 (18.3 to 10.0)
6 months 34 21.5 (7.8 to 35.3)
1 year 31 24.8 (12.5 to 37.1)
SF-12
Physical summary
1 month 29 1.7 (2.4 to 5.8)
6 months 38 6.3 (2.5 to 10.0)
1 year 35 6.6 (2.4 to 10.8)
Mental summary
1 month 29 2.8 (8.1 to 2.4)
6 months 38 1.8 (1.8 to 5.5)
1 year 35 3.0 (0.6 to 6.7)
EQ-5D utility
1 month 31 0.082 (0.178 to 0.014)
6 months 38 0.026 (0.045 to 0.097)
1 year 36 0.023 (0.033 to 0.080)
*Paired differences reﬂect changes compared with baseline.
Abbreviations as in Tables 1 and 2.KCCQ and SF-12 physical summary scores compared
with those eligible for IF access. There were no signif-
icant differences in baseline health status between the
TAVR and AVR groups in either access stratum.
WITHIN GROUP COMPARISONS. Health status data
were available for 59%, 75%, and 74% of patients
eligible for follow-up at 1 month, 6 months, and
1 year, respectively, with slightly more missing data
in the AVR arm compared with the TAVR arm,
particularly at the 1-month time point (Online
Table 1). Baseline characteristics were similar
between those with and those missing 1-month health
status data (Online Table 2), although patients
missing data were more likely to have had a major
stroke during the index hospitalization and were lessniliofemoral Group
AVR
p Value n Paired Difference* (95% CI) p Value
0.529 25 5.4 (6.2 to 17.0) 0.348
<0.001 33 16.0 (7.1 to 24.9) <0.001
<0.001 26 22.7 (14.5 to 30.8) <0.001
0.476 21 3.7 (11.5 to 18.8) 0.620
0.047 30 13.6 (3.7 to 23.5) 0.009
0.054 24 15.8 (7.1 to 24.4) 0.001
0.500 25 3.9 (7.5 to 15.3) 0.490
<0.001 33 11.2 (1.0 to 21.4) 0.033
0.002 26 19.4 (11.8 to 26.9) <0.001
0.052 25 11.3 (1.8 to 24.5) 0.088
<0.001 31 23.1 (13.3 to 32.9) <0.001
<0.001 26 31.1 (21.0 to 41.2) <0.001
0.550 16 0.8 (18.4 to 20.0) 0.932
0.003 26 11.1 (4.2 to 26.5) 0.148
<0.001 23 20.9 (8.0 to 33.9) 0.003
0.412 21 1.0 (5.7 to 3.7) 0.667
0.002 32 3.4 (0.5 to 7.2) 0.082
0.003 25 6.1 (2.1 to 10.2) 0.004
0.278 21 0.4 (6.2 to 7.0) 0.900
0.319 32 2.8 (2.8 to 8.3) 0.318
0.098 25 4.8 (0.2 to 9.9) 0.058
0.091 25 0.072 (0.171 to 0.027) 0.146
0.465 31 0.041 (0.027 to 0.109) 0.231
0.407 27 0.049 (0.005 to 0.103) 0.071
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1213likely to have been discharged to home compared
with those patients in the analytic cohort.
The unadjusted health status scores for patients by
treatment group and stratiﬁed by access site for all
time points are shown in Online Table 3. The within-
group comparisons of follow-up versus baseline
health status are shown in Table 2 (IF group) and
Table 3 (NIF group). In general, both disease-speciﬁc
and generic health status improved substantially by
1 year after TAVR or AVR, regardless of access site.
These improvements were evident by 1 month with
IF-TAVR and by 6 months with NIF-TAVR and AVR.
By 1 year, surviving patients had experienced, on
average, 19 to 24 point increases in the KCCQ overallTABLE 4 Between-Group Comparisons of Health Status After TAVR,
Iliofemoral
Adjusted Mean
Difference* TAVR-AVR
(95% CI) p Value
KCCQ
Overall summary
1 month 16.7 (12.0 to 21.3) <0.001
6 months 2.1 (1.9 to 6.1) 0.295
1 year 1.3 (3.0 to 5.5) 0.554
Physical limitations
1 month 17.8 (12.3 to 23.3) <0.001
6 months 1.6 (3.3 to 6.5) 0.518
1 year 1.6 (3.6 to 6.8) 0.545
Total symptoms
1 month 9.9 (5.6 to 14.3) <0.001
6 months 1.1 (2.6 to 4.9) 0.550
1 year 0.2 (4.4 to 3.9) 0.908
Quality of life
1 month 19.0 (13.7 to 24.3) <0.001
6 months 4.1 (0.5 to 8.6) 0.078
1 year 0.2 (4.5 to 4.9) 0.944
Social limitation
1 month 18.6 (11.8 to 25.4) <0.001
6 months 1.4 (4.2 to 7.0) 0.620
1 year 0.2 (5.7 to 6.1) 0.948
SF12
Physical
1 month 4.9 (3.1 to 6.7) <0.001
6 months 0.3 (2.1 to 1.4) 0.721
1 year 0.1 (2.0 to 2.2) 0.927
Mental
1 month 6.1 (3.8 to 8.5) <0.001
6 months 2.2 (0.3 to 4.1) 0.026
1 year 0.8 (1.3 to 3.0) 0.456
EQ5D utility
1 month 0.117 (0.075 to 0.159) <0.001
6 months 0.012 (0.021 to 0.045) 0.486
1 year 0.016 (0.019 to 0.050) 0.378
*Differences reﬂect the comparison of TAVR vs. AVR and are on the basis of longitudinal g
tem between treatment assignment and access site.
Abbreviations as in Tables 1 and 2.summary scores, 5 to 7 point increases in SF-12
physical summary scores, and 3 to 5 point increases
in SF-12 mental summary scores. At 1 year, only the
IF-TAVR group demonstrated a signiﬁcant improve-
ment in EQ-5D utilities, with an increase of 0.04
points compared with baseline.
BETWEEN-GROUP COMPARISONS. The comparisons of
health status between those patients randomized toTAVR
versus AVR, according to the longitudinal growth curve
models, areshown inTable4andFigures 1 and2. Therewas
a signiﬁcant interaction between treatment assignment
and access site for several of the key health status mea-
sures at the 1-month time point, and thus, all analyses
were stratiﬁedbyaccess site. IF-TAVRwas associatedwithStratiﬁed by Access Site
Noniliofemoral
Interaction
p Value†
Adjusted Mean
Difference* TAVR-AVR
(95% CI) p Value
3.6 (6.6 to 13.9) 0.486 0.019
4.6 (13.1 to 3.8) 0.282 0.138
2.0 (8.1 to 12.1) 0.700 0.899
1.6 (10.9 to 14.1) 0.805 0.016
7.6 (17.8 to 2.6) 0.144 0.096
0.9 (11.4 to 13.1) 0.888 0.914
2.3 (7.2 to 11.9) 0.632 0.139
3.2 (11.0 to 4.5) 0.410 0.290
0.8 (10.8 to 9.3) 0.883 0.927
8.3 (3.5 to 20.2) 0.169 0.098
2.3 (11.8 to 7.2) 0.638 0.211
1.1 (12.2 to 10.1) 0.853 0.842
7.1 (8.2 to 22.5) 0.360 0.161
1.1 (12.8 to 10.6) 0.850 0.686
8.4 (5.7 to 22.4) 0.241 0.290
3.2 (0.9 to 7.4) 0.126 0.459
0.1 (3.5 to 3.7) 0.975 0.844
2.9 (1.9 to 7.8) 0.237 0.290
0.1 (5.4 to 5.1) 0.957 0.025
1.0 (5.0 to 2.9) 0.609 0.136
1.3 (3.7 to 6.3) 0.610 0.863
0.042 (0.051 to 0.136) 0.375 0.140
0.044 (0.115 to 0.026) 0.219 0.140
0.018 (0.100 to 0.064) 0.667 0.459
rowth curve models (see Methods section for details). †The p value for the interaction
FIGURE 1 Adjusted
Results are reported
for the interaction b
replacement; TAVR ¼
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1214greater early improvement inhealth status comparedwith
AVR,with 16.7-point higherKCCQoverall summary scores
(95% conﬁdence interval: 12.0 to 21.3, p < 0.001) at 1
month. However, at 6 months and 1 year, there were no
differences between IF-TAVR and AVR in KCCQ overall
summary scores. Similar trends (signiﬁcantlybetter scores
at 1month for IF-TAVRvs.AVRwithnodifferences at later
time points) were observed for the KCCQ subscales, the
SF-12 physical and mental summary scores, and the EQ-
5D. For patients ineligible for IF access, there were no
signiﬁcant differences between TAVR and AVR for any of
the health status measures at any time points, although
conﬁdence intervals for the differences were wide due to
the much smaller sample size of the NIF cohort.
RATES OF ACCEPTABLE AND FAVORABLE OUTCOMES.
An acceptable outcome after TAVR or AVR, which com-
bines survival status with health status outcomes at 6-
month follow-up, occurred in 73% of TAVR patients
versus 64% of AVR patients (p ¼ 0.022) (Table 5). This
difference was conﬁned to the IF cohort (75% vs. 63%;
p ¼ 0.005), with no difference in the rates of favorableBetween-Group Differences in Disease-Speciﬁc Health Status Between T
separately for the iliofemoral (blue circles) and noniliofemoral (red squares) a
etween treatment group and access site at each time point. KCCQ ¼ Kansas
transcatheter aortic valve replacement.6-month outcomes between TAVR and AVR among pa-
tients in the NIF access stratum. At 1 year, the rates of
favorable outcomes did not differ signiﬁcantly between
treatment groups, regardless of access site (over-
all population TAVR vs. AVR: 58% vs. 51%; p ¼ 0.143).
PER-PROTOCOL RESULTS. Of the 709 randomized
patients who had baseline quality-of-life data, 1 TAVR
patient and 6 AVR patients did not have their assigned
procedure, and 6 TAVR patients required a change in
access site. As such, the per-protocol analytic popula-
tion included 369 TAVR patients and 327 AVR patients
who were randomized to and received their assigned
treatment. There were no notable differences in either
the within-group or between-group comparisons in
the per-protocol analysis comparedwith the intention-
to-treat analyses (Online Tables 4 to 6).
DISCUSSION
In this large, multicenter clinical trial of patients with
severe symptomatic aortic stenosis who were atAVR and SAVR, on the Basis of Longitudinal Growth Curve Models
pproach. Error bars denote 95% conﬁdence intervals. The p values are
City Cardiomyopathy Questionnaire; SAVR ¼ surgical aortic valve
FIGURE 2 Adjusted Between-Group Differences in Generic Health Status
Between TAVR and SAVR, on the Basis of Longitudinal Growth Curve
Models
Results are reported separately for the iliofemoral (blue circles) and non-
iliofemoral (red squares) approaches. Error bars denote 95% conﬁdence in-
tervals. The p values are for the interaction between treatment group and
access site at each time point. SF-12 ¼Medical Outcomes Study Short-Form 12
Questionnaire; other abbreviations as in Figure 1.
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1215increased surgical risk, surviving patients who were
treated with TAVR with a self-expanding valve or with
surgical AVR had substantial improvements in health
status. Among surviving patients eligible for IF access,
those treated with TAVR had an early health status
beneﬁt compared with AVR, with greater improve-
ments in heart failure symptoms, physical function,
and quality of life at 1 month. However, by 6 months,
there were no differences between groups, and there
was little change in health status in either group be-
tween 6 months and 1 year. Among surviving patients
who required NIF access, there were no signiﬁcant
differences between TAVR and AVR for any of the
health status measures at any of the time points.
These access-speciﬁc results are particularly in-
teresting when compared with those from Cohort A of
the PARTNER (Placement of Aortic Transcatheter
Valve) trial, which was a trial of balloon-expandable
TAVR versus AVR in patients at increased surgical
risk (4). In the PARTNER trial, there was a similarly
strong interaction between access site and early
health status beneﬁts, with those patients eligible for
transfemoral access receiving an early beneﬁt with
TAVR compared with AVR but no such beneﬁt among
those patients who underwent transapical TAVR. The
more prolonged recovery among transapical patients
was posited to reﬂect the greater pain associated
with the lateral thoracotomy required for transapical
access as compared with median sternotomy. In the
CoreValve trial, patients who required NIF access
were treated via either the subclavian artery or a
direct aortic approach—both of which might be
expected to produce less post-operative pain com-
pared with a thoracotomy. Nonetheless, our data
demonstrate that NIF-TAVR via these routes was still
associated with health status and quality-of-life out-
comes that were similar to those seen with surgical
AVR—even at the 1-month time point.
There are several potential explanations for the
apparent lack of early health status beneﬁt with
NIF-TAVR versus AVR seen in the CoreValve trial.
First, it is possible that even the ministernotomy or
minithoracotomy required for the direct aortic ap-
proach (the most common NIF approach used in the
trial) affects recovery in elderly, debilitated, and
frail patients to a similar extent as a full sterno-
tomy. Second, there may be important differences in
post-operative recovery between TAVR via the direct
aortic or subclavian approach and surgical AVR that
could not be measured by the health status in-
struments used in our study. Had we employed more
sensitive approaches (such as a visual analog pain
TABLE 5 Rates of Acceptable and Favorable Outcome After TAVR and AVR
Overall Population Iliofemoral Non-Iliofemoral
TAVR (n ¼ 394) AVR (n ¼ 401) p Value TAVR (n ¼ 330) AVR (n ¼ 333) p Value TAVR (n ¼ 64) AVR (n ¼ 68) p Value
Acceptable outcome at 6 months* 72.6 63.6 0.022 75.5 63.5 0.005 58.0 64.1 0.559
Favorable outcome at 1 year† 57.6 51.4 0.143 58.5 51.9 0.149 52.9 48.8 0.692
Values are %. *Deﬁned as death, KCCQ overall summary score <45, or decrease in KCCQ overall summary score of$10 points from baseline. †Deﬁned as death, KCCQ overall summary score<60, or decrease
in KCCQ overall summary score of $10 points from baseline.
Abbreviations as in Table 1.
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1216scale), it is possible that differences between groups
would have then been detected. Finally, it is possible
that there are important differences in early health
status between NIF-TAVR and AVR that could not
be detected because of the small sample size in the NIF
cohort of our study. Indeed, the point estimates for the
difference in SF-12 physical component scores be-
tween TAVR and AVR were similar for IF and
NIF patients (and the interaction test was nonsigniﬁ-
cant), suggesting a potential early beneﬁt in recovery
of physical function with NIF-TAVR versus AVR.
Future studies will be necessary to determine how to
optimize the health status recovery of patients
requiring NIF access and to examine whether there are
any differences among the alternative access sites.
It is also important to recognize that the health
status outcomes reported in this study apply only to
surviving patients. Because there was a survival
advantage with TAVR compared with AVR in the
CoreValve High Risk trial, it is possible that longer-
term health status beneﬁts of TAVR could have been
missed due to differential attrition of the sickest pa-
tients in the AVR group. Indeed, when we integrated
survival and quality-of-life outcomes into a single
metric, we found that patients treated with TAVR
were more likely to have an acceptable outcome at 6
months compared with patients undergoing AVR,
with a similar trend in favorable outcomes at 1 year,
regardless of access site. We believe that examining
the results of the trial in this manner is both patient-
centered and clinically relevant, because patients
considering TAVR or AVR may value more than just
survival. If a treatment saves lives but the quality of
those lives is poor, this is unlikely to be viewed as a
desirable outcome by patients or their treating phy-
sicians. Given the mortality beneﬁt seen with TAVR in
the CoreValve High-Risk trial, it is therefore en-
couraging to see that the rates of acceptable and
favorable outcomes were improved as well with TAVR
compared with AVR.
STUDY LIMITATIONS. First, due to the small sheath
size required for the CoreValve device, only a small
proportion of patients required NIF access; as such, the
comparisons of NIF-TAVR with AVR may beunderpowered to detect modest yet important differ-
ences between the 2 treatments. Because many of the
interactions of treatment by access site were highly
signiﬁcant at 1month, however, it is clear that there are
meaningful differences between IF- and NIF-TAVR in
terms of early health status recovery. Second, there
was a fair amount of missing health status data over
follow-up, particularly in the AVR arm. We used
growth curve models to analyze the health status data,
which take advantage of all data available and limit the
bias due to missing data. However, it is still possible
that missing data could have inﬂuenced our results.
Third, the trial was unblinded, which could have
inﬂuenced how patients complete the health status
assessments. Finally, the quality-of-life results are
only reported up to 1 year; thus, the durability of these
results beyond this time frame is unknown.
CONCLUSIONS
In a cohort of patients with severe aortic stenosis at
increased surgical risk, treatment with either AVR or
TAVR with the CoreValve self-expanding bio-
prosthesis results in substantial improvements in
disease-speciﬁc and generic health status. Surviving
patients treated via the IF route experienced more
rapid improvement in heart failure symptoms
and functional status compared with AVR, whereas
patients treated via the NIF route had similar health
status outcomes as AVR. Furthermore, when inte-
grating survival with quality of life, we found that
patients treated with TAVR were more likely to have
an acceptable outcome compared with patients un-
dergoing AVR. We believe that use of these combined
outcomes is particularly relevant in the elderly pop-
ulation of patients considering TAVR or AVR, as they
best represent the overarching goals of treatment
from a patient perspective.
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PERSPECTIVES
WHAT IS KNOWN? In previous studies, among patients
at increased risk for surgery, balloon-expandable TAVR via a
transfemoral approach showed improved early quality of life
and similar late outcomes compared with surgical AVR.
WHAT IS NEW? An alternative TAVR platform with a self-
expanding bioprosthesis has recently been shown to be
associated with improved survival compared with AVR in
patients at increased surgical risk, but how this device affects
patients’ symptoms, functional status, and quality of life
compared with AVR was unknown. Because the self-
expanding bioprosthesis differs from the balloon-expandable
valve in terms of the device, the routes of delivery, and the
risk of particular complications, the health status outcomes of
patients treated with these different devices may also be
different. Using data from the CoreValve High Risk Pivotal
trial, we found that—similar to the balloon-expandable
TAVR—patients eligible for IF access had an early health
status beneﬁt compared with AVR across all disease-speciﬁc
and generic health status measures, but there were no dif-
ferences between groups at later time points. In contrast,
there were no signiﬁcant health status differences at any of
the time points between TAVR and AVR for patients who
required NIF access.
WHAT IS NEXT? Future studies are needed to determine how
to optimize the health status recovery of patients requiring NIF
access and to examine whether there are any differences
among the alternative access sites (transapical, subclavian, or
transaortic).
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